原发性胆汁性胆管炎并发高脂血症的研究现状  

Research advances in primary biliary cholangitis with hyperlipidemia

作　　者：冯丽娜[1] 张晓雪 黄剑洁 马博 温晓玉[1] 陈满秋[1] 金清龙[1] FENG Lina;ZHANG Xiaoxue;HUANG Jianjie;MA Bo;WEN Xiaoyu;CHEN Manqiu;JIN Qinglong(Department of Hepatology,The First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第一医院肝病科,长春130021

出　　处：《临床肝胆病杂志》2021年第1期221-224,共4页Journal of Clinical Hepatology

基　　金：吉林省财政厅项目(JLSCZD2019-027)。

摘　　要：血脂紊乱是原发性胆汁性胆管炎(PBC)最常见的并发症之一。回顾了PBC并发高脂血症的脂质谱、相关心血管疾病风险与治疗的研究现状。不同于其他肝病,PBC并发高脂血症具有独特的脂质谱,且随病情进展动态演变。一般不认为动脉粥样硬化及心血管疾病发病风险增加。对于有治疗指征的人群,建议首选他汀类药物。未来还需要更多深入的系统性研究以明确其诊治及管理流程。Dyslipidemia is one of the most common complications of primary biliary cholangitis(PBC).This article reviews the latest research on lipid profile,the risk of cardiovascular diseases,and treatment of PBC with hyperlipidemia.Different from other liver diseases,PBC with hyperlipidemia has a unique lipid profile,which changes dynamically with disease progression.It is generally not considered that there are increased risks of atherosclerosis and cardiovascular disease.For those who have indications for treatment,statins are recommended as the first choice.In the future,more in-depth systematic studies are needed to clarify its diagnosis,treatment,and management processes.

关 键 词：肝硬化 胆汁性 高脂血症 高胆固醇血症 

分 类 号：R575.22[医药卫生—消化系统]